SELLAS Life Sciences Group (Nasdaq: $SLS): REGAL, GPS, SLS009 and the Updated AML Catalyst Story

The Full Story So Far: From WT1 Immunotherapy to a Two-Asset AML Narrative

The older SELLAS story began with GPS and the idea that WT1 could be used as a cancer immunotherapy target across multiple malignancies. WT1 has long been viewed as an attractive tumor-associated antigen because it is overexpressed in a range of cancers while having limited expression in most normal adult tissues. GPS was licensed from Memorial Sloan Kettering Cancer Center and designed to stimulate immune responses against WT1. Early development work generated enough clinical interest to support additional studies in hematologic malignancies and solid tumors, including AML and malignant pleural mesothelioma.

Over time, the market’s focus narrowed. Investors can admire platform optionality, but small-cap biotech valuations usually depend on the program closest to a decisive catalyst. For SELLAS, that program became GPS in AML. The company’s earlier clinical work suggested potential survival benefit and immune activation, but the question that mattered was whether those signals could translate into a randomized Phase 3 result strong enough to support regulatory discussion. REGAL was designed to answer that question in AML patients who reached complete remission after second-line salvage therapy and are not proceeding to transplant. That population is important because remission after salvage therapy does not equal cure; relapse risk remains high and treatment options are limited.

The REGAL timeline became central to the public story during 2024 and 2025. Enrollment had been completed, the study was event-driven, and the company communicated that final analysis would occur after 80 deaths. The Independent Data Monitoring Committee review in August 2025 recommended that the trial continue without modification. That was not a declaration of efficacy, but it was an important safety and futility milestone. A trial halted for futility would have damaged the thesis severely. Continuing without modification kept the pivotal question alive.

In late 2025 the story became more nuanced. Management and key opinion leaders discussed the fact that survival times appeared longer than originally expected, while carefully emphasizing that the trial remained blinded. On December 29, 2025, SELLAS reported that 72 events had occurred as of December 26. That was below the 80-event threshold previously expected before year-end. For traders, this fueled speculation that prolonged survival could be a positive signal. For disciplined investors, the correct interpretation was narrower: the slower event pace was interesting, potentially constructive, but not conclusive.

The May 2026 update pushed the timeline even closer to the decision point. With 78 events reported as of May 11, only two additional events were needed to trigger the final analysis process. This does not mean topline data appears immediately after event 80. SELLAS has described customary steps including database lock, blinded data review, statistical analysis, unblinding and then disclosure of topline results. But the practical meaning is clear: REGAL has moved from a “future 2026 catalyst” into an imminent late-stage biotech event window.

At the same time, SLS009 transformed the narrative from a pure GPS readout story into a broader AML development story. SELLAS licensed the asset from GenFleet Therapeutics in 2022, gaining rights outside Greater China. The mechanism, CDK9 inhibition, is relevant because CDK9 regulates transcriptional programs that include short-lived survival proteins such as MCL-1. In AML, especially after venetoclax-based therapy, MCL-1 biology is widely discussed as one path of resistance. The SLS009 thesis is that selective CDK9 inhibition may help suppress survival pathways and restore sensitivity when standard approaches fail.

The ASH 2025 data made SLS009 harder to ignore. SELLAS reported that SLS009 plus azacitidine and venetoclax achieved a 46% overall response rate across 35 evaluable relapsed/refractory AML-MR patients previously treated with venetoclax-based regimens, including 29% CR/CRi. The response rates in ASXL1 and TP53-mutated patients were particularly notable given the adverse-risk biology. Median overall survival reached 8.9 months in the least pretreated cohort, while patients with one prior line of therapy had median overall survival not yet reached at the time of reporting. These are not registrational Phase 3 data, and cross-trial comparisons must be handled carefully. But the results provided enough signal to support expansion into newly diagnosed high-risk AML.

That is why the evergreen SELLAS story should not be frozen in the older frame of “GPS or nothing.” The company remains deeply exposed to the REGAL outcome, but it now has two active AML conversations. GPS asks whether an immunotherapeutic can extend survival in a post-salvage remission population. SLS009 asks whether a selective CDK9 inhibitor can improve outcomes in high-risk AML patients, including those with biology associated with venetoclax resistance. Together, they form a more sophisticated but still very risky biotech narrative.

Management, Execution and Governance

SELLAS is led by founder, President and Chief Executive Officer Angelos M. Stergiou, M.D., Sc.D. h.c.. According to the company’s profile, Dr. Stergiou founded SELLAS and previously co-founded Genesis Life Sciences, a health economics, pricing-reimbursement and market-access company. That background is relevant because the SELLAS story does not end at clinical data. If REGAL is positive, the company would face regulatory, access, pricing, reimbursement, manufacturing and commercialization decisions. A CEO with market-access exposure may be better positioned to understand the path from trial result to real-world product strategy, although execution remains to be proven.

The current management team also includes Dragan Cicic, M.D., Senior Vice President and Chief Development Officer; John T. Burns, C.P.A., Senior Vice President and Chief Financial Officer; Andrew Elnatan, Senior Vice President of Regulatory Affairs, CMC and Quality; and Stacy E. Yeung, Vice President, General Counsel and Corporate Secretary. For a company approaching a pivotal oncology readout, the presence of regulatory, CMC and quality leadership is important. A positive trial does not automatically become an approval. The company must be able to assemble a credible regulatory package, manage manufacturing expectations, prepare for agency dialogue, and address potential review questions.

Execution so far can be viewed in two ways. On the constructive side, SELLAS completed enrollment in REGAL, passed IDMC continuation review, kept investors informed as the event-driven timeline moved later, strengthened its balance sheet through warrant exercises, presented SLS009 data at ASH, initiated earlier-line SLS009 work, and added European clinical-network collaboration through IMPACT-AML. Those are real execution points, not just promotional language.

On the skeptical side, SELLAS has also been a long-running small-cap biotech story with repeated financing needs, a history of heavy dilution, and a valuation that remains highly dependent on future events. Investors who have followed the stock for years know that promising science does not always translate into shareholder returns. Execution must be judged not only by trial progress, but also by how management protects the cap table, communicates uncertainty, handles investor expectations and avoids overpromising around blinded data.

The fairest governance view is that management has brought the company to a genuine late-stage moment. That deserves acknowledgment. But the true test lies ahead. If REGAL is positive, SELLAS must shift from clinical-stage survival mode into regulatory and strategic execution. If REGAL is negative, management must preserve credibility and explain how SLS009 can carry the company forward. Either scenario will test capital allocation and communication. In small-cap biotech, the post-data phase can be as important as the data itself.

Upcoming Catalysts and What to Watch

The first catalyst is the announcement that REGAL has reached the 80th event. Since SELLAS reported 78 events as of May 11, 2026, this trigger is close. The company has said it will provide an update and announce when the 80th event has been reached. Investors should remember that the event announcement is not the same as topline data. It starts the final analysis process.

The second catalyst is the actual REGAL topline readout. This is the defining event. Key details will include whether the study meets its primary endpoint of overall survival, the magnitude of benefit, hazard ratio, confidence interval, p-value, safety profile, censoring, subgroup consistency and any commentary on regulatory next steps. A clean positive result would be transformational. A miss would be damaging. An ambiguous result would be complex and potentially volatile.

The third catalyst is SLS009 progress in newly diagnosed AML. SELLAS has guided for topline data from the 80-patient Phase 2 study in Q4 2026. The company’s collaboration with IMPACT-AML in Europe is also relevant because it expands the clinical footprint and may help enroll biomarker-defined high-risk patients. For SLS009, investors should watch response rates, CR/CRi, MRD status if disclosed, duration of response, overall survival, safety, tolerability, dose intensity and whether the biomarker strategy appears to identify patients most likely to benefit.

The fourth catalyst is financing and strategic activity. If REGAL is positive, investors should watch whether SELLAS pursues a partner, prepares independently for BLA submission, uses the ATM, raises capital through a larger offering, or signals commercial buildout plans. If REGAL is negative, investors should watch how management prioritizes SLS009 and preserves cash.

The fifth catalyst is regulatory communication. A positive Phase 3 survival result does not automatically answer every FDA question. Investors should watch for language around BLA preparation, CMC readiness, manufacturing, safety database, statistical robustness and potential advisory-committee risk. Regulatory execution can create value or destroy momentum after a positive readout.

What Would Make the Story Stronger — and What Would Break It

The strongest possible version of the SELLAS story would require more than a headline saying that REGAL is positive. The market would want to see a clean overall-survival benefit, a clinically meaningful separation of the Kaplan-Meier curves, a hazard ratio strong enough to support confidence, a p-value that leaves little ambiguity, and a safety profile consistent with use in a vulnerable AML population. It would also want management to communicate a credible regulatory path, including BLA preparation, CMC readiness and realistic timing. In that case, GPS could become a true late-stage value anchor rather than only a speculative catalyst.

The story would become stronger again if SLS009 produces confirmatory signals in earlier-line AML. The most useful data would not simply be response rate, but response depth, durability, survival, tolerability and evidence that the biomarker strategy can identify patients who genuinely need more than standard AZA/VEN. If SLS009 shows benefit in patients unlikely to respond to venetoclax-based therapy, SELLAS could have a second asset that speaks directly to one of the major problems in AML treatment: resistance and poor outcomes in biologically adverse disease.

The story would weaken sharply if REGAL misses cleanly. A negative primary endpoint would force investors to revalue the company around SLS009, cash, remaining pipeline optionality and management’s ability to reset priorities. That does not mean SELLAS would have no value. It means the lead late-stage thesis would be broken, and the market would likely apply a much deeper discount to everything else. The same would be true if REGAL produces ambiguous results that are not clearly approvable, because small-cap biotech investors often punish uncertainty almost as hard as outright failure.

The second way the story could weaken is through poor capital execution. If SELLAS raises capital aggressively at weak prices, communicates poorly around ATM usage, or allows dilution to dominate the narrative after a major clinical update, shareholder confidence could suffer even if the science remains interesting. The company has more cash than before, which gives management room to be patient. How that room is used will matter.

The third risk is scientific overextension. A positive signal in SLS009 does not automatically validate every CDK9 hypothesis, every AML subgroup or every combination strategy. A positive REGAL result would not automatically validate GPS across all WT1-positive tumors. The best biotech management teams know how to expand carefully after success without pretending one dataset proves everything. Investors should reward disciplined development, not just aggressive storytelling.